PMID- 36564539
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2191-1991 (Print)
IS  - 2191-1991 (Electronic)
IS  - 2191-1991 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Dec 24
TI  - Health state utility values for metastatic pancreatic cancer using a composite 
      time trade-off based on the vignette-based approach in Japan.
PG  - 63
LID - 10.1186/s13561-022-00413-8 [doi]
LID - 63
AB  - BACKGROUNDS: Limited information is available on the utility values of metastatic 
      pancreatic cancer, focusing on different health statuses, selected chemotherapy, 
      and related grades 1/2 and 3/4 adverse events (AEs). We evaluated Japanese 
      societal-based health-related utility values for metastatic pancreatic cancer by 
      considering different grade toxicities commonly associated with chemotherapy 
      using the vignette-based method. METHODS: We developed health status scenarios 
      for patients with metastatic pancreatic cancer undergoing chemotherapy and 
      conducted utility research using the developed scenarios in four steps: 
      'literature review,' 'exploratory interview,' 'content validation', and 'utility 
      research'. In the development process, to consider the impact of AEs of 
      chemotherapy for metastatic pancreatic cancer on health state utility values, we 
      selected neutropenia, febrile neutropenia, diarrhea, nausea and vomiting, and 
      neuropathy as representative AEs. Each AE was classified as either grade 1/2 or 
      3/4. We confirmed our created scenarios through cognitive interviews with the 
      general population and clinical experts to validate the content. Finally, we 
      developed 11 scenarios for using 'utility research,' evaluated in a 
      societal-based valuation study using the face-to-face method. Participants for 
      'utility research' were the general population, and they evaluated these 
      scenarios in the composite time trade-off (cTTO) and visual analog scale (VAS) of 
      the European quality of life (EuroQol) valuation technology to derive health 
      state utility scores. RESULTS: Of 220 responders who completed this survey, 201 
      were adapted into the analysis population. Stable disease with no AEs (reference 
      state) had a mean utility value of 0.653 using cTTO. The lowest mean utility 
      score in the stable state was 0.242 (stable disease + grade 3/4 vomiting). VAS 
      results ranged from 0.189 to 0.468, depending on the various grades of AEs in 
      stable disease. In addition, grade 3/4 AEs and grade 1/2 nausea/vomiting were 
      associated with significantly greater disutility. Utility values were also 
      strongly influenced by the direct impact of AE on physical symptoms, severity and 
      their experience. In addition, 95.9% of the respondents agreed that they 
      understood the questions in the post-response questionnaire. CONCLUSIONS: We 
      clarified the health state utility values of patients with metastatic pancreatic 
      cancer based on the general population in Japan. The effect on utilities should 
      be considered not only for serious AEs, but also for minor AEs.
CI  - (c) 2022. The Author(s).
FAU - Takumoto, Yuki
AU  - Takumoto Y
AD  - Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 
      2-522-1 Noshio, Kiyose, Tokyo, Japan.
AD  - Center for Outcomes Research and Economic Evaluation for Health, National 
      Institute of Public Health, Saitama, Japan.
FAU - Sasahara, Yuriko
AU  - Sasahara Y
AD  - Department of Medical Oncology, Yamagata Prefectural Central Hospital, Yamagata, 
      Japan.
FAU - Narimatsu, Hiroto
AU  - Narimatsu H
AD  - Department of Genetic Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, 
      Japan.
AD  - Cancer Prevention and Cancer Control Division, Kanagawa Cancer Center Research 
      Institute, Yokohama, Kanagawa, Japan.
AD  - Graduate School of Health Innovation, Kanagawa University of Human Services, 
      Yokohama, Kanagawa, Japan.
FAU - Murata, Tatsunori
AU  - Murata T
AD  - CRECON Medical Assessment Inc, Tokyo, Japan.
FAU - Akazawa, Manabu
AU  - Akazawa M
AUID- ORCID: 0000-0002-4112-6035
AD  - Department of Public Health and Epidemiology, Meiji Pharmaceutical University, 
      2-522-1 Noshio, Kiyose, Tokyo, Japan. makazawa@my-pharm.ac.jp.
LA  - eng
GR  - 19H03874/JSPS KAKENHI/
PT  - Journal Article
DEP - 20221224
PL  - Germany
TA  - Health Econ Rev
JT  - Health economics review
JID - 101583209
EIN - Health Econ Rev. 2023 Jan 11;13(1):3. PMID: 36629978
PMC - PMC9789314
OTO - NOTNLM
OT  - Health related quality of life
OT  - Metastatic pancreatic cancer
OT  - Time trade-off
OT  - Utility
OT  - Vignette-based method
COIS- Not applicable.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/12/24
CRDT- 2022/12/23 23:37
PHST- 2022/06/28 00:00 [received]
PHST- 2022/12/12 00:00 [accepted]
PHST- 2022/12/23 23:37 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/12/24 00:00 [pmc-release]
AID - 10.1186/s13561-022-00413-8 [pii]
AID - 413 [pii]
AID - 10.1186/s13561-022-00413-8 [doi]
PST - epublish
SO  - Health Econ Rev. 2022 Dec 24;12(1):63. doi: 10.1186/s13561-022-00413-8.